AMEX · APUS
Healthcare · Drug Manufacturers - Specialty & Generic
$4.59
Up+$2.54 (+55.34%)
Updated Oct 6, 2026, 8:38 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · APUS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
APUS closed at $4.59 after 20 trading sessions, up 99.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.99 | $5.83 | $4.21 | $4.59 | 33.79M |
| Oct 2, 2026 | $4.10 | $4.16 | $3.10 | $3.22 | 138.72K |
| Oct 1, 2026 | $4.90 | $5.09 | $4.10 | $4.10 | 146.51K |
| Sep 30, 2026 | $5.04 | $5.25 | $4.72 | $5.00 | 191.51K |
| Sep 29, 2026 | $6.17 | $6.17 | $4.63 | $5.02 | 768.44K |
| Sep 28, 2026 | $6.33 | $6.50 | $5.56 | $6.39 | 858.8K |
| Sep 25, 2026 | $8.32 | $9.14 | $5.39 | $7.25 | 37.11M |
| Sep 24, 2026 | $6.99 | $8.74 | $4.61 | $4.92 | 87.85M |
| Sep 23, 2026 | $1.81 | $2.30 | $1.7446 | $2.29 | 152.53K |
| Sep 22, 2026 | $1.65 | $1.999 | $1.6128 | $1.85 | 134.82K |
| Sep 21, 2026 | $1.72 | $1.865 | $1.67 | $1.67 | 671.01K |
| Sep 18, 2026 | $1.68 | $2.10 | $1.6301 | $1.77 | 1.34M |
| Sep 17, 2026 | $1.73 | $1.92 | $1.60 | $1.67 | 84K |
| Sep 16, 2026 | $1.71 | $1.71 | $1.51 | $1.60 | 65.03K |
| Sep 15, 2026 | $2.11 | $2.1101 | $1.60 | $1.64 | 66.3K |
| Sep 14, 2026 | $2.39 | $2.39 | $2.025 | $2.09 | 29.82K |
| Sep 11, 2026 | $2.16 | $2.26 | $2.09 | $2.105 | 20.69K |
| Sep 10, 2026 | $2.26 | $2.47 | $2.12 | $2.17 | 41.16K |
| Sep 9, 2026 | $2.30 | $2.35 | $2.17 | $2.29 | 29.57K |
| Sep 8, 2026 | $2.40 | $2.405 | $2.25 | $2.30 | 17.42K |
The latest Smart Investors Daily articles mentioning APUS.
Company
Market Activity
Research & News
APUS research
Company profile and research snapshot.
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 29, 2026
MindWave Innovations Inc. ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month software development and technology services agreement with New York-based
Benzinga · Sep 24, 2026
META, P, AKAM, APUS, COST were among the stocks seen trending on Thursday, Sept. 24, 2026.
Benzinga · Sep 24, 2026
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
Benzinga · Sep 24, 2026
Apimeds shares are surging Thursday after its subsidiary MindWave Innovations announced a technology services agreement with AQUAE Holdings.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APUS.
No results
No recent SID articles mention APUS.
